Axsome Therapeutics Inc
NASDAQ:AXSM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
65.72
100.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Axsome Therapeutics Inc
Axsome Therapeutics Inc
Long-Term Debt
Axsome Therapeutics Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Axsome Therapeutics Inc
NASDAQ:AXSM
|
Long-Term Debt
$183m
|
CAGR 3-Years
55%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Long-Term Debt
$31.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Long-Term Debt
$48.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
15%
|
CAGR 10-Years
21%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Long-Term Debt
$57.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Long-Term Debt
$35B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Long-Term Debt
$29B
|
CAGR 3-Years
23%
|
CAGR 5-Years
16%
|
CAGR 10-Years
19%
|
|
Axsome Therapeutics Inc
Glance View
Axsome Therapeutics Inc. emerged as a dynamic player in the biopharmaceutical arena, driven by a resolute commitment to alleviate the burdensome effects of central nervous system (CNS) disorders. Founded with a vision to fill critical treatment gaps in neurologically influenced conditions, Axsome leverages innovative drug discovery and development to address medical needs that have long been underserved. The company focuses intently on conditions such as depression, migraine, narcolepsy, and Alzheimer's disease-related agitation, channeling resources into a streamlined pipeline that seeks to fast-track the development and commercialization of life-changing therapies. Operating at the intersection of cutting-edge science and patient-centric healthcare, Axsome generates revenue through the successful approval and marketing of its proprietary pharmaceutical products. The company's business model hinges on advancing its clinical candidates through rigorous trials, eventually gaining the necessary regulatory endorsements to bring them to market. By holding the intellectual property rights for these novel drugs, Axsome enjoys the advantages of exclusivity in the marketplace, which allows it to negotiate favorable pricing and reimbursement terms. This strategic approach not only positions Axsome as a potentially transformative force within the pharmaceutical industry but also underlines its commitment to producing viable, accessible treatments for those grappling with debilitating CNS disorders.
See Also
What is Axsome Therapeutics Inc's Long-Term Debt?
Long-Term Debt
183m
USD
Based on the financial report for Sep 30, 2024, Axsome Therapeutics Inc's Long-Term Debt amounts to 183m USD.
What is Axsome Therapeutics Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
57%
Over the last year, the Long-Term Debt growth was 3%. The average annual Long-Term Debt growth rates for Axsome Therapeutics Inc have been 55% over the past three years , 57% over the past five years .
You don't have any saved screeners yet
